Faster, Clearer Answers for Your Oncology Program
Meadowhawk’s Oncology/Pharmacology services are designed to accelerate your path from concept to candidate selection. We extend our core rodent in vivo offering with fit-for-purpose tumor models for your efficacy studies, plus integrated PK/PD analysis, and rapid, decision-ready data coordinated through a single study director.
Built on our AAALAC-accredited facility and advanced imaging and bioanalytical platforms, we provide robust efficacy and PK/PD insights to drive confident go/no-go decisions.
Meadowhawk combines big-CRO expertise with the responsiveness and collaboration that oncology innovators expect.
Start Your Pharmacology Study
Oncology/Pharmacology Platform Overview
Our platform combines cutting-edge in vivo tumor models, advanced IVIS imaging, and integrated LCMS and immunoanalytical support. Clients benefit from the same end-to-end, single-vendor experience as other Meadowhawk services, ensuring:
- Streamlined Logistics: Rapid study start-up and execution.
- Cohesive Workflow: Coordinated data delivery from test article through the complete data package.
- Decision-Focused Data: Practical insights, not one-size-fits-all study templates.
Integrated Bioanalysis and Modalities
Oncology studies are tightly integrated with Meadowhawk’s in-house LCMS and Immunoanalytical platforms, enabling a cohesive “dose to data” workflow.
Supported Drug Modalities: Supported by flexible fit-for-purpose assay strategies aligned to each program.
- Small Molecules & Chemotherapeutics
- Antibody-Drug Conjugates (ADCs)
- Cell and Gene Therapies
- RNA-based Therapeutics
Sample and Tissue Coverage
Comprehensive analysis across critical sample types:
- Tumors and tissues of origin.
- Key organs for distribution and off-target assessments.
- Blood and other biofluids to support PK, PD biomarker analysis, and safety monitoring.
The Meadowhawk Advantage
With over 100 years of hands-on experience in the field of oncology, each study is led by a dedicated, highly skilled Study Director who serves as your single point of contact. This expert oversees the design, execution, and reporting, ensuring consistent communication and proactive problem-solving throughout your project. They are backed by a cross-functional team experienced in in vivo pharmacology, bioanalysis, and oncology models.
Models and Study Capabilities
We support a broad range of murine oncology models, enabling alignment with diverse mechanisms of action and immuno-oncology strategies.
- Syngeneic: B16F10 (melanoma), MC38 and CT26 (colon adenocarcinoma)
- Xenograft: MDA-MB-231 (breast cancer), HT-29 (colorectal adenocarcinoma)
- Metastatic/Other: N87 (gastric carcinoma, metastasis), A549 (lung carcinoma)
- CDX & Humanized: Cell Line–Derived Xenograft (CDX) and Humanized mouse models
Recent Updated Models and Progress
| On-going Model Establishment | |||
| Cell Line | Mice Strain | Disease Indication (s) | Stage Status |
| B16F10 | C57/BL/6J (F) | Melanoma | Cell proliferation/inoculation/growth curve/SOC |
| MDA-MB-231 | Athymic Nude (F) | Breast cancer | Cell proliferation/inoculation/growth curve/SOC |
| A549 | Athymic Nude (F) | Lung carcinoma | Cell proliferation/inoculation/growth curve/SOC |
| HT-29 | Athymic Nude (F) | Colorectal adenocarcinoma | Cell proliferation/inoculation/growth curve/SOC |
| CT26 | Bulb-C (F) | Colon carcinoma | Cell proliferation/inoculation/growth curve/SOC |
| N87 | Athymic Nude (F) | Gastric carcinoma (metastasis) | Cell proliferation/inoculation/growth curve |
| MC38 | C57/BL/6J (F) | Colon adenocarcinoma | Cell proliferation/inoculation/growth curve/SOC |
| MM.1S | Nod Scid (F) | Multiple myeloma | Cell proliferation/inoculation/growth curve/SOC |
| NCI-H929 | Athymic Nude (F) | Multiple myeloma | Cell proliferation |
Need a specific model? Additional tumor lines are available upon request. We collaborate closely to align model selection, endpoints, and analytics to each molecule and mechanism.
Key Endpoints and Data Outputs
We deliver accurate and actionable data to inform your development pipeline.
- Efficacy Endpoints:
- Tumor volume, captured with direct-data-capture calipers for accuracy.
- Metastasis incidence and counts.
- Survival tracking.
- PK/PD Profiles:
- Mechanistic readouts integrating bioanalytical data from tumors, blood, and other tissues.
- Clear linkage between exposure, response, and tolerability.
- Standardized Reporting:
- Weekly updates on tumor volumes and body weights.
- Configurable Excel summary files.
- Formal Word reports as requested.
AAALAC-Accredited Vivarium
Our work is anchored in a state-of-the-art, AAALAC-accredited vivarium in Boston. We utilize Innovive IVC mouse racks to support both immunocompetent and immunocompromised mouse models under the highest standards of welfare and compliance.
Advanced Data Capture and Imaging
- Procedure Rooms: Dedicated BSL2 biosafety cabinets, integrated computers, and directly connected calipers and scales enable high-throughput, accurate data capture and fast turnaround.
- Imaging: IVIS Lumina 3 imaging supports live and ex vivo bioluminescence and fluorescence, enabling longitudinal tumor burden and metastasis tracking with minimal animal use.
- Software: StudyLog Oncology software standardizes workflows and minimizes manual error in study design, scheduling, randomization, data acquisition, analysis, and reporting.